Takeda highlights potential solution to payer assessment challenges for advanced therapies

13 November 2018

Findings presented by Japan’s largest drugmaker Takeda (TYO: 4502) at ISPOR 2018 report that where standards of care are not clearly defined in terms of cost or outcomes, the ability of payers to accurately estimate the cost effectiveness of new therapeutic options can be hindered. This may mean that payer decisions to reimburse innovative therapies may be delayed or rejected, potentially impacting patient care.

The posters being presented on this topic by Takeda explore a potential solution to this issue: performance-based risk-sharing agreements (PBRSAs), which could contribute to improved future patient care, and the role of patient registries in supporting these agreements.

Highlights of the posters

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK